Paul F Robbins

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy
    Paul F Robbins
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 173:7125-30. 2004
  2. pmc Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions
    Paul F Robbins
    Surgery Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    J Immunol 180:6116-31. 2008
  3. pmc Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1
    Paul F Robbins
    National Institutes of Health, National Cancer Institute, Surgery Branch, Bethesda, MD 20892 1201, USA
    J Clin Oncol 29:917-24. 2011
  4. pmc Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions
    Marybeth S Hughes
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Hum Gene Ther 16:457-72. 2005
  5. pmc Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma
    Paul F Robbins
    Surgery Branch, National Cancer Institute, National Institutes of Health, Building 10, Room 2B42, Bethesda, MD 20892 7502, USA
    J Immunol 169:6036-47. 2002
  6. pmc Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma
    Steven A Rosenberg
    Center for Cancer Research, Surgery Branch, National Cancer Institute, National Institute of Health, Building 10, Room 2B42, 10 Center Drive, Bethesda, Maryland 20892, USA
    J Immunother 26:385-93. 2003
  7. pmc High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens
    Richard A Morgan
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 171:3287-95. 2003
  8. pmc Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines
    Yangbing Zhao
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 174:4415-23. 2005
  9. pmc Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression
    Jennifer A Wargo
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 58:383-94. 2009
  10. pmc Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy
    Juhua Zhou
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother 28:53-62. 2005

Collaborators

Detail Information

Publications58

  1. pmc Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy
    Paul F Robbins
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 173:7125-30. 2004
    ....
  2. pmc Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions
    Paul F Robbins
    Surgery Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    J Immunol 180:6116-31. 2008
    ....
  3. pmc Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1
    Paul F Robbins
    National Institutes of Health, National Cancer Institute, Surgery Branch, Bethesda, MD 20892 1201, USA
    J Clin Oncol 29:917-24. 2011
    ....
  4. pmc Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions
    Marybeth S Hughes
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Hum Gene Ther 16:457-72. 2005
    ..TCR-transduced T-cells are thus attractive candidates for evaluation in cell transfer therapies of patients with cancer...
  5. pmc Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma
    Paul F Robbins
    Surgery Branch, National Cancer Institute, National Institutes of Health, Building 10, Room 2B42, Bethesda, MD 20892 7502, USA
    J Immunol 169:6036-47. 2002
    ..These observations provide an impetus to develop strategies directed toward generating HLA class II-restricted tumor-reactive T cells...
  6. pmc Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma
    Steven A Rosenberg
    Center for Cancer Research, Surgery Branch, National Cancer Institute, National Institute of Health, Building 10, Room 2B42, 10 Center Drive, Bethesda, Maryland 20892, USA
    J Immunother 26:385-93. 2003
    ....
  7. pmc High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens
    Richard A Morgan
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 171:3287-95. 2003
    ..These results suggest that lymphocytes genetically engineered to express anti-gp100 TCR may be of value in the adoptive immunotherapy of patients with melanoma...
  8. pmc Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines
    Yangbing Zhao
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 174:4415-23. 2005
    ..These results strongly support the idea that redirection of normal T cell specificity by TCR gene transfer can have potential applications in tumor adoptive immunotherapy...
  9. pmc Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression
    Jennifer A Wargo
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 58:383-94. 2009
    ..These results have relevance for TCR-based gene therapies targeting common epithelial malignancies...
  10. pmc Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy
    Juhua Zhou
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother 28:53-62. 2005
    ....
  11. pmc Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy
    Jianping Huang
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 176:7726-35. 2006
    ..004) with the ability of these TILs to mediate tumor regression following adoptive transfer...
  12. pmc Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens
    Mark E Dudley
    Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892 1201, USA
    J Clin Oncol 26:5233-9. 2008
    ..Here, we update that study and evaluate the safety and efficacy of two increased-intensity myeloablative lymphodepleting regimens...
  13. pmc Induction of CD4+ Th1 lymphocytes that recognize known and novel class II MHC restricted epitopes from the melanoma antigen gp100 by stimulation with recombinant protein
    Maria R Parkhurst
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1502, USA
    J Immunother 27:79-91. 2004
    ..These results suggest that recombinant tumor-associated proteins may be clinically applicable for the generation of CD4+ T helper cells in active vaccination strategies or adoptive cellular immunotherapies...
  14. pmc Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
    Mark E Dudley
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20902, USA
    Science 298:850-4. 2002
    ..This approach presents new possibilities for the treatment of patients with cancer as well as patients with human immunodeficiency virus-related acquired immunodeficiency syndrome and other infectious diseases...
  15. pmc Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1
    Christopher E Touloukian
    National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 170:1579-85. 2003
    ..Thus, the tumor-bearing state reverses, in part, the tolerance of T cells that results from the normal expression of tissue differentiation Ags...
  16. pmc Bcl-2 overexpression enhances tumor-specific T-cell survival
    Jehad Charo
    Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Res 65:2001-8. 2005
    ..Our data suggest that adoptive immunotherapy approaches to the treatment of cancer patients may be enhanced using Bcl-2-modified tumor-reactive T cells...
  17. pmc Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy
    Khoi Q Tran
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1201, USA
    J Immunother 31:742-51. 2008
    ....
  18. pmc Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells
    Maria R Parkhurst
    Surgery Branch, National Cancer Institute NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 15:169-80. 2009
    ..To develop an immunotherapy for patients with cancers that overexpress CEA, we isolated and genetically modified a T-cell receptors (TCRs) that specifically bound a CEA peptide on human cancer cells...
  19. pmc Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression
    Jianping Huang
    Surgery Branch, National Cancer Institute, National Institute of Health, Bethesda, Maryland 20892, USA
    J Immunother 28:258-67. 2005
    ....
  20. pmc Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2
    Bianca Heemskerk
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Hum Gene Ther 19:496-510. 2008
    ..In this study, insertion of the IL-2 gene into antitumor TILs increased their ability to survive after IL-2 withdrawal in vitro but did not increase their in vivo persistence or clinical effectiveness...
  21. pmc Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene
    Cary Hsu
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 109:5168-77. 2007
    ..It does not appear that the retroviral vector integration sites played a role in the continuous growth of this cell clone, but this remains under investigation...
  22. pmc Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma
    Juhua Zhou
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 173:7622-9. 2004
    ..A similar analysis may also be useful for monitoring autoimmune responses...
  23. pmc Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes
    Laura A Johnson
    Surgery Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    J Immunol 177:6548-59. 2006
    ..We propose that inducing expression of this highly avid TCR in patient PBMC has the potential to induce tumor regression, as an "off-the-shelf" reagent for allogeneic melanoma patient gene therapy...
  24. pmc Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy
    Steven A Rosenberg
    Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Clin Cancer Res 17:4550-7. 2011
    ..We investigated the ability of adoptive cell transfer utilizing autologous tumor-infiltrating lymphocytes (TIL) to mediate durable complete regressions in heavily pretreated patients with metastatic melanoma...
  25. pmc T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product
    Jianping Huang
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 172:6057-64. 2004
    ....
  26. pmc Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy
    Richard A Morgan
    Surgery Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Immunother 36:133-51. 2013
    ....
  27. pmc Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy
    Christian S Hinrichs
    National Cancer Institute, Bethesda, MD, USA
    Blood 117:808-14. 2011
    ..Thus, these data suggest that naive cells resist terminal differentiation, or "exhaustion," maintain high replicative potential, and therefore may be the superior subset for use in adoptive immunotherapy...
  28. pmc Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond
    Cyrille J Cohen
    Surgery Branch, Center for Cancer Research, National Cancer Institute NIH, 10 Center Drive, Bethesda, MD 20892, USA
    Cancer Res 67:3898-903. 2007
    ..Preferential pairing of cysteine-modified receptor chains accounts for these observations, which could have significant implications for the improvement of TCR gene therapy...
  29. pmc MHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cells
    J Mark Sloan
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Cancer Gene Ther 9:946-50. 2002
    ..This study describes the simultaneous presentation of a tumor-associated antigen to both CD4(+) and CD8(+) T cells and lends support to the use of gene-modified DCs as a means to initiate both CD4(+) and CD8(+) antitumor responses...
  30. pmc Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression
    Yong Chen Lu
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 190:6034-42. 2013
    ..This study also provides an impetus to develop personalized immunotherapy targeting tumor-specific, mutated Ags...
  31. pmc Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design
    Gang Zeng
    Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 62:3630-5. 2002
    ..Dual-specific peptides containing both cytotoxic T-cell and helper T-cell epitopes may represent an attractive strategy of vaccine design aimed at generating tumor-reactive CD4+ and CD8+ T cells...
  32. pmc T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis
    Maria R Parkhurst
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Mol Ther 19:620-6. 2011
    ..It also emphasizes the destructive power of small numbers of highly avid T cells and the limitations of using CEA as a target for cancer immunotherapy...
  33. pmc Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase
    Maria R Parkhurst
    National Cancer Institute, Surgery Branch and National Heart, Lung, and Blood Institute, Hematology Branch, NIH, Bethesda, Maryland 20892 1502, USA
    Clin Cancer Res 10:4688-98. 2004
    ..Therefore, we initiated a clinical protocol to evaluate the therapeutic and immunological efficacy of this peptide...
  34. pmc Irradiation enhances human T-cell function by upregulating CD70 expression on antigen-presenting cells in vitro
    Jianping Huang
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother 34:327-35. 2011
    ..Radiation therapy may therefore enhance T-cell activation in vivo through the CD27 pathway by virtue of its ability to upregulate the expression of CD70 on antigen-presenting cells...
  35. ncbi request reprint Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer
    Eric Tran
    Surgery Branch, National Cancer Institute NCI, National Institutes of Health, Bethesda, MD 20892, USA
    Science 344:641-5. 2014
    ..These results provide evidence that a CD4+ T cell response against a mutated antigen can be harnessed to mediate regression of a metastatic epithelial cancer...
  36. doi request reprint A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer
    Nachimuthu Chinnasamy
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 186:685-96. 2011
    ..On the basis of these results, a clinical trial is planned in which patients bearing a variety of tumor histologies will receive autologous PBLs that have been transduced with this optimized anti-MAGE-A3 TCR...
  37. pmc Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy
    Daniel J Powell
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1201, USA
    Blood 105:241-50. 2005
    ....
  38. pmc Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy
    Juhua Zhou
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 175:7046-52. 2005
    ....
  39. pmc Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions
    Yong Chen Lu
    Authors Affiliations Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland and
    Clin Cancer Res 20:3401-10. 2014
    ..However, the antigen targets recognized by these effective TILs remain largely unclear...
  40. pmc Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma
    Qiong J Wang
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Cancer Res 72:6119-29. 2012
    ..Our results suggest that RCC-reactive TIL do exist in situ, but may be difficult to recover and study because of proliferative exhaustion, driven by tumor-expressed CD70...
  41. pmc Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer
    Xin Yao
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 119:5688-96. 2012
    ..All 5 clinical trials are registered at www.clinicaltrials.gov as NCT00001832, NCT00096382, NCT00335127, NCT00509496, and NCT00513604...
  42. pmc High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines
    Yangbing Zhao
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 179:5845-54. 2007
    ..Although the biological activity of these two relatively low-affinity TCRs was comparable to wild-type reactivity in CD8(+) T cells, introduction of these TCR dramatically increased the reactivity of CD4(+) T cells to tumor cell lines...
  43. pmc Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function
    Christopher E Touloukian
    National Cancer Institute, NIH, Building 10, Room 2B42, Bethesda, MD 20892, USA
    Cancer Res 62:5144-7. 2002
    ..These findings indicate that antigens expressed by malignant melanoma cells can partially activate CD4(+) T lymphocytes...
  44. pmc Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytes
    Cristina Maccalli
    Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892 1502, USA
    Cancer Res 63:6735-43. 2003
    ..Therefore, this alteration may either affect the localization or the processing of this gene product, which may at least in part be responsible for the differential recognition of tumor and normal cells...
  45. pmc Expression of New York esophageal squamous cell carcinoma-1 in primary and metastatic melanoma
    Phyu P Aung
    Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Hum Pathol 45:259-67. 2014
    ..These findings provide evidence of the value of this specific adoptive cell transfer therapy for the treatment of metastatic melanoma. ..
  46. pmc Characterization of T-cell receptors directed against HLA-A*01-restricted and C*07-restricted epitopes of MAGE-A3 and MAGE-A12
    Shigui Zhu
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Immunother 35:680-8. 2012
    ..These results provide support for the use of these TCRs in cancer adoptive immunotherapy trials...
  47. doi request reprint A novel murine T-cell receptor targeting NY-ESO-1
    Shannon F Rosati
    Surgery Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD
    J Immunother 37:135-46. 2014
    ..This new mTCR targeted to NY-ESO-1 represents a novel potential therapeutic option for adoptive cell-transfer therapy for a variety of malignancies. ..
  48. pmc Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
    Paul F Robbins
    Surgery Branch, National Cancer Institute, National Institutes of Health NIH, Bethesda, Maryland, USA
    Nat Med 19:747-52. 2013
    ....
  49. ncbi request reprint Contrasting effects of FLIPL overexpression in human T cells on activation-induced cell death and cytokine production
    Jehad Charo
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Leukoc Biol 81:1297-302. 2007
    ..The multiple effects of FLIPL indicate that this protein may influence T cell responses to antigenic stimulation...
  50. ncbi request reprint Clonal persistence and evolution during a decade of recurrent melanoma
    Ena Wang
    Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
    J Invest Dermatol 126:1372-7. 2006
    ..Thus, metastatic melanoma recurs from a common progenitor cell and phenotypic changes occur around a central core of genetic stability. This observation may bear significance for the development of targeted anticancer therapies...
  51. pmc Identification of BING-4 cancer antigen translated from an alternative open reading frame of a gene in the extended MHC class II region using lymphocytes from a patient with a durable complete regression following immunotherapy
    Steven A Rosenberg
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 2B42, Bethesda, MD 20892, USA
    J Immunol 168:2402-7. 2002
    ..Overexpression was not found in normal tissues or other tumor types. Thus, BING-4 represents another candidate Ag for possible use in the immunotherapy of patients with melanoma...
  52. pmc Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy
    Simon Turcotte
    Authors Affiliations Surgery Branch and Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, Maryland
    Clin Cancer Res 20:331-43. 2014
    ..To evaluate whether patients with metastatic gastrointestinal adenocarcinomas refractory to chemotherapy harbor tumor-reactive cytotoxic T cells...
  53. doi request reprint NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis
    Jin Ping Lai
    Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Mod Pathol 25:854-8. 2012
    ..Beyond its role in patient selection for targeted therapy, immunohistochemistry for NY-ESO-1 may be diagnostically useful for the distinction of synovial sarcoma from other spindle cell neoplasms...
  54. pmc Longitudinal study of recurrent metastatic melanoma cell lines underscores the individuality of cancer biology
    Zoltan Pos
    1 Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA 2 Hungarian Academy of Sciences Semmelweis University Lendület Experimental and Translational Immunomics Research Group, Budapest, Hungary 3 Department of Genetics, Cell, and Immunobiology, Semmelweis University, Budapest, Hungary
    J Invest Dermatol 134:1389-96. 2014
    ....
  55. ncbi request reprint Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: implications as a potential biomarker
    Gang Zeng
    Department of Urology and Jonsson Comprehensive Cancer Center, 66 118 Center for Health Sciences, David Geffen School of Medicine at UCLA, Box 951738, Los Angeles, CA 90095, USA
    Int J Cancer 114:268-73. 2005
    ..This simple and straightforward approach may allow the investigation of the clinical significance of spontaneous Ab responses against multiple TAA and their correlation with the clinical course of malignant diseases in the future...
  56. ncbi request reprint Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine
    Xianzheng Zhou
    Division of Immunology and Hematopoiesis, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Cancer Res 65:1079-88. 2005
    ....
  57. ncbi request reprint Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen
    Luisa Novellino
    Unit of Immunotherapy of Human Tumors and Unit of Molecular Mechanisms of Tumor Growth and Progression, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    J Immunol 170:6363-70. 2003
    ..These findings further support the relevance of CD4(+) T cells directed against mutated epitopes in tumor immunity and provide the rationale for a possible usage of mutated, tumor-specific Ags for immunotherapy of human cancer...
  58. ncbi request reprint NKG2D engagement of colorectal cancer-specific T cells strengthens TCR-mediated antigen stimulation and elicits TCR independent anti-tumor activity
    Cristina Maccalli
    Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Via Venezian 1, I 20133 Milan, Italy
    Eur J Immunol 33:2033-43. 2003
    ..Taken together these data indicate that the engagement of NKG2D, depending on the expression of its ligands by target cells, can influence the pattern of anti-tumor reactivity by T lymphocytes...